Johnson & Johnson has rewarded shareholders with a quarterly dividend. As a Dividend King, it is the epitome of a steady and ...

In Friday's hearing, which lasted 10 hours, U.S. Bankruptcy Judge Christopher Lopez heard closing arguments in Johnson & ...

JNJ's $14B acquisition of ITCI bolsters its portfolio with Caplyta, showing strong sales and patent protection until 2033.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

BofA raised the firm’s price target on Johnson & Johnson (JNJ) to $171 from $159 and keeps a Neutral rating on the shares. For the last ...